Why the study?
Platelet FcγRIIa expression predicts ischemic complications after PCI, prompting evaluation of its cost-effectiveness as a tool to guide individualized DAPT duration.
Does platelet FcγRIIa-assay-guided DAPT duration improve cost-effectiveness in acute MI patients treated with PCI compared to standard 12-month DAPT?
Does platelet FcγRIIa-assay-guided DAPT duration improve cost-effectiveness in acute MI patients treated with PCI compared to standard 12-month DAPT?
Answers are grounded in this paper and cite their sources.
A platelet FcγRIIa-assay to guide DAPT duration after PCI in MI patients is projected to be highly cost-effective, with an ICER of $436 per QALY gained.
OBJECTIVE: Duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) influences ischemic and bleeding events. Platelet expression of constant fragment of immunoglobulin, low affinity IIa, receptor (FcγRIIa) independently predicts risk of ischemic complications and is proposed as a tool to guide individualized care. METHODS: We used a Markov model to predict lifetime ischemic and bleeding events and healthcare costs in acute myocardial infarction (MI) patients treated with PCI and DAPT and to project cost-effectiveness of platelet FcγRIIa-assay-guided care (30:3 months DAPT for patients at high: low ischemic risk) versus current standard care (12 months DAPT) from the perspective of the US healthcare system. Model inputs included assay sensitivity and specificity, ischemic and bleeding event rates, and impacts on quality of life, mortality, and costs. Assay cost was $90. Sensitivity analyses were conducted over a range of plausible clinical and cost assumptions. RESULTS: Under base case assumptions, platelet FcγRIIa-assay-guided DAPT duration was projected to increase lifetime costs by $19 versus standard care, with an associated incremental cost-effectiveness ratio (ICER) of $436 per quality-adjusted life-year (QALY) gained. Assay-guided DAPT duration was consistent with high-value care (ICER < $50 000/QALY gained) over a broad range of alternative assumptions. CONCLUSION: Based on a decision-analytic model, for patients with MI treated with PCI, the additional costs of the platelet FcγRIIa assay for guiding DAPT duration would be largely offset by reductions in downstream event-related costs, and assay-guided care would be highly cost-effective by current standards. These findings require confirmation in prospective studies and in a randomized clinical trial of assay-guided versus nonassay-guided DAPT duration.
No takes yet. Share an insight, caveat, or question.
Vilain et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: